The "better safety in drug supply" bill (GSAV) will be adopted before this year's parliamentary summer recess - and it will bring some revisions for advanced therapies. Experts from G-BA and umbrella payer group GKV-Spitzenverband as well as a member of Parliament will review the changes for reimbursement and collection of post-launch data.
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.